Laurent Peyrin-Biroulet

List of Publications by Citations

644 papers	31,468 citations	87 h-index	161 g-index
707 ext. papers	40,575 ext. citations	6.1 avg, IF	7.76 L-index

#	Paper	IF	Citations
644	Ulcerative colitis. *Lancet, The*, **2017**, 389, 1756-1770	40	1146
643	3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. *Journal of Crohn's and Colitis*, **2017**, 11, 3-25	1.5	1087
642	Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. *Nature Genetics*, **2011**, 43, 246-52	36.3	1028
641	Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. *American Journal of Gastroenterology*, **2015**, 110, 1324-38	0.7	1024
640	Crohn's disease. *Lancet, The*, **2017**, 389, 1741-1755	40	829
639	The natural history of adult Crohn's disease in population-based cohorts. *American Journal of Gastroenterology*, **2010**, 105, 289-97	0.7	641
638	Iron deficiency anaemia. *Lancet, The*, **2016**, 387, 907-16	40	611
637	Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. *Clinical Gastroenterology and Hepatology*, **2012**, 10, 639-45	6.9	549
636	Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. *Clinical Gastroenterology and Hepatology*, **2008**, 6, 644-53	6.9	462
635	Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. *Journal of Crohn's and Colitis*, **2013**, 7, 556-85	1.5	438
634	Development of the Crohn's disease digestive damage score, the Lémann score. *Inflammatory Bowel Diseases*, **2011**, 17, 1415-22	4.5	395
633	Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. *New England Journal of Medicine*, **2019**, 381, 1201-1214	59.2	354
632	Clinical implications of mucosal healing for the management of IBD. *Nature Reviews Gastroenterology and Hepatology*, **2010**, 7, 15-29	24.2	347
631	Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. *Gastroenterology*, **2011**, 141, 1621-28.e1-5	13.3	337
630	Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. *Gut*, **2014**, 63, 88-95	19.2	325
629	Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 1663-1672	6.9	285
628	Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. *American Journal of Gastroenterology*, **2011**, 106, 674-84	0.7	280

627	Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. *Gastroenterology*, **2015**, 148, 1035-1058.e3	13.3	251
626	Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. *American Journal of Gastroenterology*, **2013**, 108, 1268-76	0.7	247
625	Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. *Journal of Crohn's and Colitis*, **2011**, 5, 477-83	1.5	247
624	Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. *Clinical Gastroenterology and Hepatology*, **2015**, 13, 847-58.e4; quiz e48-50	6.9	246
623	Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. *New England Journal of Medicine*, **2019**, 381, 1215-1226	59.2	240
622	Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. *Gastroenterology*, **2013**, 145, 166-175.e8	13.3	228
621	Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. *Clinical Gastroenterology and Hepatology*, **2016**, 14, 1385-1397.e10	6.9	219
620	Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. *Clinical Gastroenterology and Hepatology*, **2016**, 14, 348-354.e17	6.9	217
619	Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. *Gut*, **2012**, 61, 241-7	19.2	216
618	Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. *Clinical Gastroenterology and Hepatology*, **2014**, 12, 80-84.e2	6.9	215
617	Review article: the natural history of postoperative Crohn's disease recurrence. *Alimentary Pharmacology and Therapeutics*, **2012**, 35, 625-33	6.1	215
616	Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. *Gut*, **2014**, 63, 423-32	19.2	211
615	Diffusion-weighted magnetic resonance without bowel preparation for detecting colonic inflammation in inflammatory bowel disease. *Gut*, **2010**, 59, 1056-65	19.2	203
614	Surgery in a population-based cohort of Crohn's disease from Olmsted County, Minnesota (1970-2004). *American Journal of Gastroenterology*, **2012**, 107, 1693-701	0.7	199
613	Development and validation of the Nancy histological index for UC. *Gut*, **2017**, 66, 43-49	19.2	196
612	Biologic agents for IBD: practical insights. *Nature Reviews Gastroenterology and Hepatology*, **2015**, 12, 537-45	24.2	196
611	Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. *American Journal of Gastroenterology*, **2009**, 104, 2089-96	0.7	193
610	STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. *Gastroenterology*, **2021**, 160, 1570-1583	13.3	191

609	Treat to target: a proposed new paradigm for the management of Crohn's disease. *Clinical Gastroenterology and Hepatology*, **2015**, 13, 1042-50.e2	6.9	190
608	Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. *Journal of Crohn's and Colitis*, **2016**, 10, 395-401	1.5	184
607	Ulcerative colitis. *Nature Reviews Disease Primers*, **2020**, 6, 74	51.1	182
606	Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. *Gut*, **2011**, 60, 930-6	19.2	177
605	Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. *Gastroenterology*, **2016**, 150, 1568-1578	13.3	171
604	Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease. *Gut*, **2012**, 61, 78-85	19.2	171
603	Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. *Inflammatory Bowel Diseases*, **2013**, 19, 2568-76	4.5	170
602	Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease. *Gastroenterology*, **2018**, 154, 1343-1351.e1	13.3	164
601	Application of Artificial Intelligence to Gastroenterology and Hepatology. *Gastroenterology*, **2020**, 158, 76-94.e2	13.3	162
600	Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review. *Clinical Gastroenterology and Hepatology*, **2018**, 16, 343-356.e3	6.9	161
599	Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials. *Alimentary Pharmacology and Therapeutics*, **2017**, 45, 1291-1302	6.1	160
598	Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. *Annals of Internal Medicine*, **2014**, 160, 704-11	8	158
597	Surgery for adult Crohn's disease: what is the actual risk?. *Gut*, **2011**, 60, 1178-81	19.2	158
596	Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. *Clinical Gastroenterology and Hepatology*, **2014**, 12, 1246-56.e6	6.9	157
595	Environmental Risk Factors for Inflammatory Bowel Diseases: An Umbrella Review of Meta-analyses. *Gastroenterology*, **2019**, 157, 647-659.e4	13.3	155
594	Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases. *Gastroenterology*, **2017**, 152, 351-361.e5	13.3	153
593	Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review. *American Journal of Clinical Nutrition*, **2015**, 102, 1585-94	7	150
592	IBD immunopathogenesis: A comprehensive review of inflammatory molecules. *Autoimmunity Reviews*, **2017**, 16, 416-426	13.6	149

591	ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update. *Journal of Crohn's and Colitis*, **2017**, 11, 26-34	1.5	148
590	Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts. *Inflammatory Bowel Diseases*, **2011**, 17, 471-8	4.5	148
589	Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. *American Journal of Gastroenterology*, **2014**, 109, 1250-6	0.7	143
588	Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis. *Journal of Crohn's and Colitis*, **2013**, 7, 853-67	1.5	142
587	Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease. *Clinical Gastroenterology and Hepatology*, **2016**, 14, 1593-1601.e2	6.9	141
586	Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents. *Clinical Gastroenterology and Hepatology*, **2016**, 14, 242-50.e1-2	6.9	135
585	A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. *American Journal of Gastroenterology*, **2010**, 105, 2617-25	0.7	135
584	Ulcerative colitis as a progressive disease: the forgotten evidence. *Inflammatory Bowel Diseases*, **2012**, 18, 1356-63	4.5	133
583	Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab. *Clinical Gastroenterology and Hepatology*, **2013**, 11, 975-81.e1-4	6.9	132
582	Crohn's disease. *Nature Reviews Disease Primers*, **2020**, 6, 22	51.1	131
581	Diagnostic delay in Crohn's disease is associated with a complicated disease course and increased operation rate. *American Journal of Gastroenterology*, **2013**, 108, 1744-53; quiz 1754	0.7	128
580	Epidemiology of inflammatory bowel diseases: new insights from a French population-based registry (EPIMAD). *Digestive and Liver Disease*, **2013**, 45, 89-94	3.3	128
579	Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis. *Alimentary Pharmacology and Therapeutics*, **2017**, 45, 3-13	6.1	127
578	Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. *Clinical Gastroenterology and Hepatology*, **2010**, 8, 1048-55	6.9	127
577	Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study. *Gut*, **2018**, 67, 53-60	19.2	126
576	Dietary beliefs and behavior among inflammatory bowel disease patients. *Inflammatory Bowel Diseases*, **2013**, 19, 66-72	4.5	121
575	Histologic remission: the ultimate therapeutic goal in ulcerative colitis?. *Clinical Gastroenterology and Hepatology*, **2014**, 12, 929-34.e2	6.9	120
574	Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. *Inflammatory Bowel Diseases*, **2012**, 18, 1042-7	4.5	120

573	Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study. *Gut*, **2015**, 64, 243-9	19.2	113
572	Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics*, **2014**, 39, 447-58	6.1	112
571	Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III). *Journal of Crohn's and Colitis*, **2014**, 8, 31-44	1.5	111
570	Review article: remission rates achievable by current therapies for inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics*, **2011**, 33, 870-9	6.1	111
569	Comparing histological activity indexes in UC. *Gut*, **2015**, 64, 1412-8	19.2	103
568	IOIBD technical review on endoscopic indices for Crohn's disease clinical trials. *Gut*, **2016**, 65, 1447-55	19.2	102
567	Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies. *Journal of Crohn's and Colitis*, **2014**, 8, 469-79	1.5	101
566	A Systematic Review of Factors Associated with Non-Adherence to Treatment for Immune-Mediated Inflammatory Diseases. *Advances in Therapy*, **2015**, 32, 983-1028	4.1	101
565	Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review. *Inflammatory Bowel Diseases*, **2013**, 19, 1528-33	4.5	98
564	Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. *Gut*, **2014**, 63, 1416-23	19.2	94
563	Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials. *Clinical Gastroenterology and Hepatology*, **2015**, 13, 2233-40.e1-2; quiz e177-8	6.9	92
562	Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. *Therapeutic Advances in Gastroenterology*, **2015**, 8, 66-82	4.7	92
561	Deep remission in inflammatory bowel disease: looking beyond symptoms. *Current Gastroenterology Reports*, **2013**, 15, 315	5	91
560	A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review. *American Journal of Gastroenterology*, **2019**, 114, 874-883	0.7	90
559	Early Crohn disease: a proposed definition for use in disease-modification trials. *Gut*, **2010**, 59, 141-7	19.2	88
558	Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis. *Alimentary Pharmacology and Therapeutics*, **2018**, 47, 454-465	6.1	87
557	Systematic review: Monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD. *Gut*, **2014**, 63, 1843-53	19.2	86
556	One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. *Alimentary Pharmacology and Therapeutics*, **2017**, 46, 310-321	6.1	85

555	Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis. *Gastroenterology*, **2016**, 150, 380-8.e4	13.3	85
554	Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience. *Alimentary Pharmacology and Therapeutics*, **2013**, 37, 998-1004	6.1	84
553	Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis. *Gastroenterology*, **2020**, 158, 1554-1573.e12	13.3	84
552	Anti-TNF therapy in inflammatory bowel diseases: a huge review. *Minerva Gastroenterologica E Dietologica*, **2010**, 56, 233-43	1.6	83
551	Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort. *Gut*, **2017**, 66, 588-596	19.2	82
550	Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools: A Nationwide Survey of Patients with Inflammatory Bowel Disease. *Inflammatory Bowel Diseases*, **2017**, 23, 1425-1433	4.5	82
549	Crohn's disease: beyond antagonists of tumour necrosis factor. *Lancet, The*, **2008**, 372, 67-81	40	80
548	Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial. *Alimentary Pharmacology and Therapeutics*, **2017**, 46, 142-149	6.1	79
547	Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis. *Inflammatory Bowel Diseases*, **2014**, 20, 1288-95	4.5	79
546	Next generation of small molecules in inflammatory bowel disease. *Gut*, **2017**, 66, 199-209	19.2	78
545	Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis. *Journal of Autoimmunity*, **2017**, 80, 10-27	15.5	78
544	Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience. *American Journal of Gastroenterology*, **2015**, 110, 1186-96	0.7	78
543	Systematic review: outcomes and post-operative complications following colectomy for ulcerative colitis. *Alimentary Pharmacology and Therapeutics*, **2016**, 44, 807-16	6.1	78
542	Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. *Inflammatory Bowel Diseases*, **2012**, 18, 2063-71	4.5	77
541	Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. *Alimentary Pharmacology and Therapeutics*, **2016**, 43, 252-61	6.1	77
540	Systematic review: The epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics*, **2014**, 40, 3-15	6.1	76
539	Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process. *American Journal of Gastroenterology*, **2012**, 107, 1770-6	0.7	76
538	Systematic Review of Tumor Necrosis Factor Antagonists in Extraintestinal Manifestations in Inflammatory Bowel Disease. *Clinical Gastroenterology and Hepatology*, **2017**, 15, 25-36.e27	6.9	75

537	Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease. *Gastroenterology*, **2020**, 158, 2123-2138.e8	13.3	75
536	Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. *American Journal of Gastroenterology*, **2010**, 105, 1142-9	0.7	75
535	Modulation of sphingosine-1-phosphate in inflammatory bowel disease. *Autoimmunity Reviews*, **2017**, 16, 495-503	13.6	74
534	Patient-reported Outcomes in a French Nationwide Survey of Inflammatory Bowel Disease Patients. *Journal of Crohn's and Colitis*, **2017**, 11, 165-174	1.5	74
533	Development of an index to define overall disease severity in IBD. *Gut*, **2018**, 67, 244-254	19.2	73
532	Meta-analysis: hyperhomocysteinaemia in inflammatory bowel diseases. *Alimentary Pharmacology and Therapeutics*, **2011**, 34, 1173-84	6.1	73
531	Disability in inflammatory bowel diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health. *Inflammatory Bowel Diseases*, **2010**, 16, 15-22	4.5	73
530	Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients From the Nancy and Milan Cohorts. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 2134-2135	6.9	71
529	Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study. *Alimentary Pharmacology and Therapeutics*, **2018**, 47, 906-912	6.1	67
528	Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. *Journal of Gastroenterology*, **2018**, 53, 1048-1064	6.9	67
527	Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease. *Alimentary Pharmacology and Therapeutics*, **2015**, 42, 977-89	6.1	67
526	Novel therapeutic targets for inflammatory bowel disease. *Journal of Autoimmunity*, **2017**, 85, 103-116	15.5	66
525	Biosimilars in IBD: from theory to practice. *Nature Reviews Gastroenterology and Hepatology*, **2017**, 14, 22-31	24.2	66
524	The effect of immune therapy on surgical site infection following Crohn's Disease resection. *British Journal of Surgery*, **2013**, 100, 1089-93	5.3	66
523	Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease. *Journal of Crohn's and Colitis*, **2015**, 9, 525-31	1.5	65
522	Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics*, **2014**, 40, 363-73	6.1	65
521	Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus. *Alimentary Pharmacology and Therapeutics*, **2017**, 45, 801-813	6.1	64
520	Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn's and Ulcerative Colitis Associations. *Journal of Crohn's and Colitis*, **2017**, 11, 128-133	1.5	64

519	Moving towards disease modification in inflammatory bowel disease therapy. *Current Opinion in Gastroenterology*, **2013**, 29, 397-404	3	63
518	Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis. *Gastroenterology*, **2020**, 158, 550-561	13.3	63
517	Detection of Dysplasia or Cancer in 3.5% of Patients With Inflammatory Bowel Disease and Colonic Strictures. *Clinical Gastroenterology and Hepatology*, **2015**, 13, 1770-5	6.9	62
516	Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases. *Pharmacology & Therapeutics*, **2016**, 159, 110-9	13.9	62
515	Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn's Disease or Ulcerative Colitis: A Systematic Review and Meta-analysis. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 838-846.e2	6.9	62
514	Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort. *Alimentary Pharmacology and Therapeutics*, **2018**, 47, 485-493	6.1	61
513	Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease. *Clinical Gastroenterology and Hepatology*, **2014**, 12, 1324-9	6.9	61
512	Early intervention in Crohn's disease: towards disease modification trials. *Gut*, **2017**, 66, 2179-2187	19.2	60
511	H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. *Gut*, **2011**, 60, 456-62	19.2	60
510	Big data in IBD: a look into the future. *Nature Reviews Gastroenterology and Hepatology*, **2019**, 16, 312-321	24.2	58
509	Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease. *Expert Review of Gastroenterology and Hepatology*, **2016**, 10, 915-27	4.2	56
508	JAK inhibition in inflammatory bowel disease. *Expert Review of Clinical Immunology*, **2017**, 13, 693-703	5.1	55
507	JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?. *Gut*, **2019**, 68, 1893-1899	19.2	55
506	Improving quality of care in inflammatory bowel disease: what changes can be made today?. *Journal of Crohn's and Colitis*, **2014**, 8, 919-26	1.5	55
505	Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics*, **2017**, 45, 1179-1192	6.1	54
504	Bowel Damage as Assessed by the Lémann Index is Reversible on Anti-TNF Therapy for Crohn's Disease. *Journal of Crohn's and Colitis*, **2015**, 9, 633-9	1.5	52
503	Clinical risk factors for complicated disease: how reliable are they?. *Digestive Diseases*, **2012**, 30 Suppl 3, 67-72	3.2	52
502	Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience. *Alimentary Pharmacology and Therapeutics*, **2018**, 47, 588-595	6.1	51

501	Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics*, **2015**, 41, 1227-36	6.1	51
500	Inflammatory Bowel Disease Management During the COVID-19 Outbreak: The Ten Do's and Don'ts from the ECCO-COVID Taskforce. *Journal of Crohn's and Colitis*, **2020**, 14, S798-S806	1.5	51
499	Intravenous Versus Oral Iron for the Treatment of Anemia in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Medicine (United States)*, **2016**, 95, e2308	1.8	51
498	The nocebo effect: a clinical challenge in the era of biosimilars. *Expert Review of Clinical Immunology* , **2018**, 14, 739-749	5.1	49
497	Thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel disease: a meta-analysis. *Clinical Gastroenterology and Hepatology*, **2014**, 12, 1793-1800.e1	6.9	49
496	Incidence of and impact of medications on colectomy in newly diagnosed ulcerative colitis in the era of biologics. *Inflammatory Bowel Diseases*, **2012**, 18, 1641-6	4.5	49
495	Paradoxical gastrointestinal effects of interleukin-17 blockers. *Annals of the Rheumatic Diseases*, **2020**, 79, 1132-1138	2.4	49
494	Mortality and cancer in pediatric-onset inflammatory bowel disease: a population-based study. *American Journal of Gastroenterology*, **2013**, 108, 1647-53	0.7	48
493	Does anti-TNF therapy reduce the requirement for surgery in ulcerative colitis? A systematic review. *Current Drug Targets*, **2011**, 12, 1440-7	3	48
492	Crohn's Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With Adalimumab. *American Journal of Gastroenterology*, **2016**, 111, 1806-1815	0.7	48
491	Development of Red Flags Index for Early Referral of Adults with Symptoms and Signs Suggestive of Crohn's Disease: An IOIBD Initiative. *Journal of Crohn's and Colitis*, **2015**, 9, 601-6	1.5	47
490	Treatment of extraintestinal manifestations in inflammatory bowel disease. *Digestion*, **2012**, 86 Suppl 1, 28-35	3.6	47
489	Magnetic resonance enterography is feasible and reliable in multicenter clinical trials in patients with Crohn's disease, and may help select subjects with active inflammation. *Alimentary Pharmacology and Therapeutics*, **2016**, 43, 61-72	6.1	47
488	First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?. *Nature Reviews Gastroenterology and Hepatology*, **2013**, 10, 345-51	24.2	46
487	Surgical rates in the era of biological therapy: up, down or unchanged?. *Current Opinion in Gastroenterology*, **2017**, 33, 246-253	3	45
486	Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial. *Gut*, **2020**, 69, 1206-1212	19.2	45
485	High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn's Disease. *Clinical Gastroenterology and Hepatology*, **2018**, 16, 892-899.e2	6.9	45
484	Gastroenterology review and perspective: the role of cross-sectional imaging in evaluating bowel damage in Crohn disease. *American Journal of Roentgenology*, **2011**, 197, 42-9	5.4	45

483	Review article: the natural history of paediatric-onset ulcerative colitis in population-based studies. *Alimentary Pharmacology and Therapeutics*, **2016**, 43, 346-55	6.1	45
482	Incidence and Phenotype at Diagnosis of Very-early-onset Compared with Later-onset Paediatric Inflammatory Bowel Disease: A Population-based Study [1988-2011]. *Journal of Crohn's and Colitis*, **2017**, 11, 519-526	1.5	44
481	Diagnosis, prevention and treatment of postoperative Crohn's disease recurrence. *Digestive and Liver Disease*, **2012**, 44, 453-60	3.3	44
480	Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study. *American Journal of Gastroenterology*, **2016**, 111, 1428-1436	0.7	44
479	Genetic Factors Interact With Tobacco Smoke to Modify Risk for Inflammatory Bowel Disease in Humans and Mice. *Gastroenterology*, **2017**, 153, 550-565	13.3	43
478	Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey. *The Lancet Gastroenterology and Hepatology*, **2020**, 5, 631-632	18.8	43
477	Comorbidities in inflammatory bowel disease: a call for action. *The Lancet Gastroenterology and Hepatology*, **2019**, 4, 643-654	18.8	43
476	Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases. *Alimentary Pharmacology and Therapeutics*, **2013**, 38, 914-24	6.1	43
475	Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review. *Journal of Gastroenterology*, **2017**, 52, 19-25	6.9	43
474	Diagnostic delay in a French cohort of Crohn's disease patients. *Journal of Crohn's and Colitis*, **2014**, 8, 964-9	1.5	43
473	An endoscopic Mayo score of 0 is associated with a lower risk of colectomy than a score of 1 in ulcerative colitis. *Gut*, **2015**, 64, 1181-2	19.2	42
472	Development of the IBD Disk: A Visual Self-administered Tool for Assessing Disability in Inflammatory Bowel Diseases. *Inflammatory Bowel Diseases*, **2017**, 23, 333-340	4.5	42
471	Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy. *Alimentary Pharmacology and Therapeutics*, **2017**, 45, 50-62	6.1	42
470	Evolving definitions of remission in Crohn's disease. *Inflammatory Bowel Diseases*, **2013**, 19, 1645-53	4.5	42
469	Evolving therapeutic goals in ulcerative colitis: towards disease clearance. *Nature Reviews Gastroenterology and Hepatology*, **2020**, 17, 1-2	24.2	42
468	Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study. *Inflammatory Bowel Diseases*, **2018**, 24, 2442-2451	4.5	42
467	Review article: the histological assessment of disease activity in ulcerative colitis. *Alimentary Pharmacology and Therapeutics*, **2015**, 42, 957-67	6.1	41
466	Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study. *Journal of Crohn's and Colitis*, **2018**, 12, 1385-1391	1.5	40

465	Colorectal cancer in inflammatory bowel diseases: a population-based study (1976-2008). *Inflammatory Bowel Diseases*, **2012**, 18, 2247-51	4.5	40
464	Comparative Accuracy of Bowel Ultrasound Versus Magnetic Resonance Enterography in Combination With Colonoscopy in Assessing Crohn's Disease and Guiding Clinical Decision-making. *Journal of Crohn's and Colitis*, **2018**, 12, 1280-1287	1.5	39
463	Prevention and treatment of postoperative Crohn's disease recurrence with anti-TNF therapy: a meta-analysis of controlled trials. *Digestive and Liver Disease*, **2015**, 47, 191-6	3.3	39
462	Systematic Review on Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: It Is Time to Take Stock. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 2689-2700	6.9	38
461	Ulcerative Colitis and Crohn's Disease Have Similar Burden and Goals for Treatment. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 14-23	6.9	38
460	Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives. *Journal of Crohn's and Colitis*, **2018**, 12, 610-620	1.5	37
459	Bacterial sensor triggering receptor expressed on myeloid cells-2 regulates the mucosal inflammatory response. *Gastroenterology*, **2013**, 144, 346-356.e3	13.3	37
458	Impact of Treatment-Related Beliefs on Medication Adherence in Immune-Mediated Inflammatory Diseases: Results of the Global ALIGN Study. *Advances in Therapy*, **2017**, 34, 91-108	4.1	37
457	The prevalence of inflammatory sacroiliitis assessed on magnetic resonance imaging of inflammatory bowel disease: a retrospective study performed on 186 patients. *Alimentary Pharmacology and Therapeutics*, **2014**, 39, 957-62	6.1	36
456	Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. *Lancet, The*, **2021**, 397, 2372-2384	40	36
455	Metagenomic analysis of intestinal mucosa revealed a specific eukaryotic gut virome signature in early-diagnosed inflammatory bowel disease. *Gut Microbes*, **2019**, 10, 149-158	8.8	36
454	Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis. *Alimentary Pharmacology and Therapeutics*, **2017**, 45, 1058-1072	6.1	35
453	Photodynamic therapy as a new treatment modality for inflammatory and infectious conditions. *Expert Review of Clinical Immunology*, **2015**, 11, 637-57	5.1	35
452	Clinical trials in ulcerative colitis: a historical perspective. *Journal of Crohn's and Colitis*, **2015**, 9, 580-8	1.5	35
451	Colorectal cancer prevention in patients with ulcerative colitis. *Baillière's Best Practice and Research in Clinical Gastroenterology*, **2018**, 32-33, 103-109	2.5	35
450	Activation of the VEGFC/VEGFR3 Pathway Induces Tumor Immune Escape in Colorectal Cancer. *Cancer Research*, **2019**, 79, 4196-4210	10.1	34
449	ECCO Position Paper: Harmonization of the Approach to Ulcerative Colitis Histopathology. *Journal of Crohn's and Colitis*, **2020**, 14, 1503-1511	1.5	34
448	Development and validation of a patient-reported disability measurement tool for patients with inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics*, **2013**, 37, 438-44	6.1	34

447	MFSD2A Promotes Endothelial Generation of Inflammation-Resolving Lipid Mediators and Reduces Colitis in Mice. *Gastroenterology*, **2017**, 153, 1363-1377.e6	13.3	34
446	Histologic features predicting postoperative Crohn's disease recurrence. *Inflammatory Bowel Diseases*, **2015**, 21, 468-75	4.5	34
445	Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience. *Therapeutic Advances in Gastroenterology*, **2019**, 12, 1756284819848631	4.7	33
444	What is the patient's perspective: How important are patient-reported outcomes, quality of life and disability?. *Digestive Diseases*, **2010**, 28, 463-71	3.2	33
443	The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. *Drugs*, **2020**, 80, 99-113	12.1	32
442	Deep remission: a new concept?. *Digestive Diseases*, **2012**, 30 Suppl 3, 107-11	3.2	32
441	Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study. *American Journal of Gastroenterology*, **2020**, 115, 738-745	0.7	32
440	Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases. *Gastroenterology*, **2019**, 157, 1032-1043.e1	13.3	31
439	Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients. *Alimentary Pharmacology and Therapeutics*, **2019**, 49, 1181-1187	6.1	31
438	Interventions to Improve Adherence in Patients with Immune-Mediated Inflammatory Disorders: A Systematic Review. *PLoS ONE*, **2015**, 10, e0145076	3.7	31
437	Janus kinase inhibition with tofacitinib: changing the face of inflammatory bowel disease treatment. *Current Drug Targets*, **2013**, 14, 1385-91	3	31
436	Positioning Therapies in Ulcerative Colitis. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 1280-1290.e1	6.1	30
435	Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease. *Expert Opinion on Biological Therapy*, **2016**, 16, 1277-90	5.4	30
434	The use of azathioprine in Crohn's disease during pregnancy and in the post-operative setting: a worldwide survey of experts. *Alimentary Pharmacology and Therapeutics*, **2011**, 33, 707-13	6.1	30
433	Optimizing thiopurine therapy in inflammatory bowel disease. *Inflammatory Bowel Diseases*, **2011**, 17, 1428-35	4.5	30
432	Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study. *Inflammatory Bowel Diseases*, **2017**, 23, 2048-2053	4.5	29
431	Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study. *Alimentary Pharmacology and Therapeutics*, **2019**, 50, 40-53	6.1	29
430	Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus. *Digestive Diseases*, **2019**, 37, 266-283	3.2	29

429	Review article: faecal calprotectin and histologic remission in ulcerative colitis. *Alimentary Pharmacology and Therapeutics*, **2020**, 51, 689-698	6.1	29
428	Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review. *Clinical Gastroenterology and Hepatology*, **2018**, 16, 1407-1419.e22	6.9	29
427	Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease. *Gastroenterology*, **2018**, 155, 76-87	13.3	29
426	Systematic review and meta-analysis: assessment of factors affecting disability in inflammatory bowel disease and the reliability of the inflammatory bowel disease disability index. *Alimentary Pharmacology and Therapeutics*, **2018**, 47, 6-15	6.1	29
425	Prevalence of Bowel Damage Assessed by Cross-Sectional Imaging in Early Crohn's Disease and its Impact on Disease Outcome. *Journal of Crohn's and Colitis*, **2017**, 11, 274-280	1.5	29
424	Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials. *Digestive and Liver Disease*, **2015**, 47, 356-64	3.3	29
423	Infliximab for refractory ulcerative proctitis. *Alimentary Pharmacology and Therapeutics*, **2010**, 31, 1178-85	6.1	29
422	Submucosal plexitis as a predictor of postoperative surgical recurrence in Crohn's disease. *Inflammatory Bowel Diseases*, **2013**, 19, 1654-61	4.5	28
421	Risk of melanoma in patients who receive thiopurines for inflammatory bowel disease is not increased. *American Journal of Gastroenterology*, **2012**, 107, 1443-4	0.7	28
420	Microscopic features of colorectal neoplasia in inflammatory bowel diseases. *World Journal of Gastroenterology*, **2014**, 20, 3164-72	5.6	28
419	Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience. *Journal of Crohn's and Colitis*, **2016**, 10, 516-24	1.5	28
418	Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. *Clinical Gastroenterology and Hepatology*, **2018**, 16, 637-647.e13	6.9	27
417	Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial. *Gut*, **2019**, 68, 1162-1168	19.2	27
416	PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	27
415	Inflammatory Bowel Diseases and COVID-19: The Invisible Enemy. *Gastroenterology*, **2020**, 158, 2302-2304	13.3	27
414	The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics*, **2017**, 45, 533-541	6.1	26
413	Vedolizumab Trough Levels and Histological Healing During Maintenance Therapy in Ulcerative Colitis. *Journal of Crohn's and Colitis*, **2019**, 13, 970-975	1.5	26
412	A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn's disease. *Expert Opinion on Drug Safety*, **2016**, 15, 493-501	4.1	26

411	Perianal Crohn's disease findings other than fistulas in a population-based cohort. *Inflammatory Bowel Diseases*, **2012**, 18, 43-8	4.5	26
410	Insight into the role of TSLP in inflammatory bowel diseases. *Autoimmunity Reviews*, **2017**, 16, 55-63	13.6	26
409	Impact of immunosuppressive therapy on hepatitis B vaccination in inflammatory bowel diseases. *European Journal of Gastroenterology and Hepatology*, **2015**, 27, 877-81	2.2	26
408	Colonoscopic perforations in inflammatory bowel disease: a retrospective study in a French referral centre. *Digestive and Liver Disease*, **2013**, 45, 569-72	3.3	26
407	Diagnostic Delay Is Associated with a Greater Risk of Early Surgery in a French Cohort of Crohn's Disease Patients. *Digestive Diseases and Sciences*, **2016**, 61, 3278-3284	4	25
406	Treatment algorithms in Crohn's - up, down or something else?. *Baillière's Best Practice and Research in Clinical Gastroenterology*, **2014**, 28, 473-83	2.5	25
405	Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel Disease. *Clinical Pharmacology and Therapeutics*, **2017**, 102, 633-641	6.1	25
404	Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations. *Current Medicinal Chemistry*, **2019**, 26, 259-269	4.3	25
403	Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study. *Alimentary Pharmacology and Therapeutics*, **2020**, 51, 1039-1046	6.1	25
402	Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience. *Inflammatory Bowel Diseases*, **2017**, 23, 976-985	4.5	24
401	It is Time to Revise the STRIDE Guidelines Determining Therapeutic Goals for Treat-to-Target in Inflammatory Bowel Disease. *Journal of Crohn's and Colitis*, **2018**, 12, 509	1.5	24
400	Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: Systematic review and network meta-analysis. *British Journal of Clinical Pharmacology*, **2018**, 84, 239-251	3.8	24
399	Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months - Multicenter European cohort study. *Digestive and Liver Disease*, **2016**, 48, 592-600	3.3	24
398	Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis. *Digestive and Liver Disease*, **2020**, 52, 268-273	3.3	24
397	Histological Remission in Ulcerative Colitis: Under the Microscope Is the Cure. *American Journal of Gastroenterology*, **2020**, 115, 179-189	0.7	23
396	Cancer and inflammatory bowel disease in the elderly. *Digestive and Liver Disease*, **2016**, 48, 1105-11	3.3	23
395	Systematic review: the financial burden of surgical complications in patients with ulcerative colitis. *Alimentary Pharmacology and Therapeutics*, **2015**, 41, 1066-78	6.1	22
394	Effectiveness Research in Inflammatory Bowel Disease: A Necessity and a Methodological Challenge. *Journal of Crohn's and Colitis*, **2016**, 10, 1096-102	1.5	22

393	Noninvasive Multimodal Methods to Differentiate Inflamed vs Fibrotic Strictures in Patients With Crohn's Disease. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 2397-2415	6.9	22
392	Treat to Target: The Role of Histologic Healing in Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 1800-1813.e4	6.9	22
391	Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 1366-1376.e2	6.9	22
390	Modern use of 5-aminosalicylic acid compounds for ulcerative colitis. *Expert Opinion on Biological Therapy*, **2020**, 20, 363-378	5.4	22
389	Compliance with the faecal calprotectin test in patients with inflammatory bowel disease. *United European Gastroenterology Journal*, **2017**, 5, 702-707	5.3	21
388	Benefit of Earlier Anti-TNF Treatment on IBD Disease Complications?. *Journal of Crohn's and Colitis*, **2015**, 9, 997-1003	1.5	21
387	Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study. *Digestive and Liver Disease*, **2016**, 48, 601-7	3.3	21
386	Preventing postoperative recurrence in Crohn's disease: what does the future hold?. *Drugs*, **2013**, 73, 1749-59	12.1	21
385	Identification of areas of functioning and disability addressed in inflammatory bowel disease-specific patient reported outcome measures. *Journal of Crohn's and Colitis*, **2012**, 6, 507-17	1.5	21
384	Inflammatory bowel disease: estimates from the global burden of disease 2017 study. *Alimentary Pharmacology and Therapeutics*, **2020**, 51, 261-270	6.1	21
383	The Selective Sphingosine 1-Phosphate Receptor Modulator Etrasimod Regulates Lymphocyte Trafficking and Alleviates Experimental Colitis. *Journal of Pharmacology and Experimental Therapeutics*, **2019**, 369, 311-317	4.7	20
382	Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAID. *American Journal of Gastroenterology*, **2020**, 115, 1812-1820	0.7	20
381	Safety of biological therapies in ulcerative colitis: An umbrella review of meta-analyses. *Baillière's Best Practice and Research in Clinical Gastroenterology*, **2018**, 32-33, 43-47	2.5	20
380	Clinical trials in luminal Crohn's disease: a historical perspective. *Journal of Crohn's and Colitis*, **2014**, 8, 1339-50	1.5	20
379	Head-to-head trials in inflammatory bowel disease: past, present and future. *Nature Reviews Gastroenterology and Hepatology*, **2020**, 17, 365-376	24.2	20
378	Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review. *Journal of Crohn's and Colitis*, **2019**, 13, 1569-1577	1.5	19
377	Vedolizumab for perianal Crohn's disease: a multicentre cohort study in 151 patients. *Alimentary Pharmacology and Therapeutics*, **2020**, 51, 719-727	6.1	19
376	Review article: treating-to-target for inflammatory bowel disease-associated anaemia. *Alimentary Pharmacology and Therapeutics*, **2018**, 48, 610-617	6.1	19

375	Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe. *Expert Review of Pharmacoeconomics and Outcomes Research*, **2017**, 17, 597-606	2.2	18
374	Vedolizumab Therapy is Ineffective for Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A GETAID Multicentre Cohort Study. *Journal of Crohn's and Colitis*, **2019**, 13, 1239-1247	1.5	18
373	Is the Pharmacokinetic Profile of a First Anti-TNF Predictive of the Clinical Outcome and Pharmacokinetics of a Second Anti-TNF?. *Inflammatory Bowel Diseases*, **2018**, 24, 2078-2085	4.5	18
372	Methotrexate for psoriasiform lesions associated with anti-tumour necrosis factor therapy in inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics*, **2012**, 35, 1175-80	6.1	18
371	Preventing disability in inflammatory bowel disease. *Therapeutic Advances in Gastroenterology*, **2017**, 10, 865-876	4.7	18
370	Features of Fecal and Colon Microbiomes Associate With Responses to Biologic Therapies for Inflammatory Bowel Diseases: A Systematic Review. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 1054-1069	6.9	18
369	Bispecific antibodies: The next generation of targeted inflammatory bowel disease therapies. *Autoimmunity Reviews*, **2019**, 18, 123-128	13.6	18
368	Will the Quality of Research Remain the Same During the COVID-19 Pandemic?. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 2142	6.9	18
367	Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study. *Journal of Clinical Medicine*, **2020**, 9,	5.1	17
366	Systematic review with meta-analysis: biologics and risk of infection or cancer in elderly patients with inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics*, **2020**, 51, 820-830	6.1	17
365	Combination Therapy With Vedolizumab and Tofacitinib in a Patient With Ulcerative Colitis and Spondyloarthropathy. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 794-796	6.9	17
364	Challenges in the Pathophysiology, Diagnosis and Management of Intestinal Fibrosis in Inflammatory Bowel Disease. *Gastroenterology*, **2019**,	13.3	17
363	Anti-tumor necrosis factor-□monotherapy versus combination therapy with an immunomodulator in IBD. *Gastroenterology Clinics of North America*, **2014**, 43, 441-56	4.4	17
362	IgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease: impact on infliximab retreatment. *European Journal of Gastroenterology and Hepatology*, **2015**, 27, 1200-8	2.2	17
361	Use of Cross-Sectional Imaging for Tight Monitoring of Inflammatory Bowel Diseases. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 1309-1323.e4	6.9	17
360	Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis. *Gastroenterology*, **2020**, 159, 2052-2064	13.3	17
359	Natural History of Crohn's Disease in Elderly Patients Diagnosed Over the Age of 70 Years: A Population-Based Study. *Inflammatory Bowel Diseases*, **2016**, 22, 1698-707	4.5	16
358	Accuracy of Diffusion-weighted Magnetic Resonance Imaging in Detecting Mucosal Healing and Treatment Response, and in Predicting Surgery, in Crohn's Disease. *Journal of Crohn's and Colitis*, **2018**, 12, 1180-1190	1.5	16

357	E-health in inflammatory bowel diseases: More challenges than opportunities?. *Digestive and Liver Disease*, **2017**, 49, 1320-1326	3.3	16
356	Ulcerative proctitis is a frequent location of paediatric-onset UC and not a minor disease: a population-based study. *Gut*, **2017**, 66, 1912-1917	19.2	16
355	Letter: infliximab de-escalation based on trough levels in patients with inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics*, **2015**, 42, 939-40	6.1	16
354	Implementing changes in clinical practice to improve the management of Crohn's disease. *Journal of Crohn's and Colitis*, **2012**, 6 Suppl 2, S235-42	1.5	16
353	Microscopic features for initial diagnosis and disease activity evaluation in inflammatory bowel disease. *Inflammatory Bowel Diseases*, **2013**, 19, 1745-52	4.5	16
352	Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review. *Current Medicinal Chemistry*, **2019**, 26, 270-279	4.3	16
351	SARS-CoV-2 vaccination in IBD: more pros than cons. *Nature Reviews Gastroenterology and Hepatology*, **2021**, 18, 211-213	24.2	16
350	Vaccination and Risk for Developing Inflammatory Bowel Disease: A Meta-Analysis of Case-Control and Cohort Studies. *Clinical Gastroenterology and Hepatology*, **2015**, 13, 1405-15.e1; quiz e130	6.9	15
349	Preventing Collateral Damage in Crohn's Disease: The Lémann Index. *Journal of Crohn's and Colitis*, **2016**, 10, 495-500	1.5	15
348	Conditions of prescription of anti-TNF agents in newly treated patients with inflammatory bowel disease in France (2011-2013). *Digestive and Liver Disease*, **2016**, 48, 620-5	3.3	15
347	Disease-modifying anti-inflammatory bowel disease drugs (DMAIDs): the missing term in the literature. *American Journal of Gastroenterology*, **2013**, 108, 859-60	0.7	15
346	Mucosal healing with anti-TNF antibodies. *Digestion*, **2012**, 86 Suppl 1, 16-22	3.6	15
345	Urinary tract infections in hospitalized inflammatory bowel disease patients: a 10-year experience. *Inflammatory Bowel Diseases*, **2012**, 18, 697-702	4.5	15
344	Endoscopy in inflammatory bowel disease: recommendations from the IBD Committee of the French Society of Digestive Endoscopy (SFED). *Endoscopy*, **2013**, 45, 936-43	3.4	15
343	The extra burden of infliximab infusions in inflammatory bowel disease. *Inflammatory Bowel Diseases*, **2013**, 19, 2464-7	4.5	15
342	Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD. *Gastroenterology*, **2021**, 160, 1452-1460.e21	13.3	15
341	Changes in inflammatory bowel disease patients' perspectives on biosimilars: A follow-up survey. *United European Gastroenterology Journal*, **2019**, 7, 1345-1352	5.3	15
340	Two Cases of Successful Ustekinumab Treatment for Non-infectious Uveitis Associated With Crohn's Disease. *Journal of Crohn's and Colitis*, **2020**, 14, 571	1.5	15

339	Previous Exposure to Multiple Anti-TNF Is Associated with Decreased Efficiency in Preventing Postoperative Crohn's Disease Recurrence. *Journal of Crohn's and Colitis*, **2017**, 11, 281-288	1.5	14
338	Tolerability of one hour 10mg/kg infliximab infusions in inflammatory bowel diseases: a prospective multicenter cohort study. *Journal of Crohn's and Colitis*, **2014**, 8, 161-5	1.5	14
337	French national consensus clinical guidelines for the management of ulcerative colitis. *Digestive and Liver Disease*, **2016**, 48, 726-33	3.3	14
336	Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses. *United European Gastroenterology Journal*, **2019**, 7, 1285-1303	5.3	14
335	Effectiveness of golimumab in ulcerative colitis: A review of the real world evidence. *Digestive and Liver Disease*, **2019**, 51, 327-334	3.3	14
334	Effectiveness And Safety Of Ustekinumab Intensification At 90 Mg Every Four Weeks In Crohn's Disease: A Multicenter Study. *Journal of Crohn's and Colitis*, **2020**,	1.5	14
333	Positioning Ustekinumab in Crohn's Disease: From Clinical Evidence to Clinical Practice. *Journal of Crohn's and Colitis*, **2017**, 11, 1258-1266	1.5	13
332	French national consensus clinical guidelines for the management of Crohn's disease. *Digestive and Liver Disease*, **2017**, 49, 368-377	3.3	13
331	SFED recommendations for IBD endoscopy during COVID-19 pandemic: Italian and French experience. *Nature Reviews Gastroenterology and Hepatology*, **2020**, 17, 507-516	24.2	13
330	Treatment Algorithms for Crohn's Disease. *Digestion*, **2020**, 101 Suppl 1, 43-57	3.6	13
329	Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study. *Alimentary Pharmacology and Therapeutics*, **2020**, 51, 852-860	6.1	13
328	Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: A nationwide case series. *Digestive and Liver Disease*, **2018**, 50, 668-674	3.3	13
327	Pneumococcal and influenza vaccine uptake in adults with inflammatory bowel disease in France: Results from a web-based study. *Digestive and Liver Disease*, **2018**, 50, 563-567	3.3	13
326	Diffusion-weighted MRI in inflammatory bowel disease. *The Lancet Gastroenterology and Hepatology*, **2018**, 3, 433-443	18.8	13
325	Risk of Incident Cancer in Inflammatory Bowel Disease Patients Starting Anti-TNF Therapy While Having Recent Malignancy. *Inflammatory Bowel Diseases*, **2016**, 22, 1362-9	4.5	13
324	Ustekinumab for Extra-intestinal Manifestations of Inflammatory Bowel Disease: A Systematic Literature Review. *Journal of Crohn's and Colitis*, **2021**, 15, 1236-1243	1.5	13
323	Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group. *Digestive and Liver Disease*, **2020**, 52, 138-142	3.3	13
322	A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease. *Alimentary Pharmacology and Therapeutics*, **2020**, 51, 553-564	6.1	13

321	Biosimilars of adalimumab: the upcoming challenge in IBD. *Expert Opinion on Biological Therapy*, **2019**, 19, 1023-1030	5.4	13
320	Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 1673-1679.e1	6.9	13
319	OP37 Efficacy and safety of ustekinumab as maintenance therapy in ulcerative colitis: Week 44 results from UNIFI. *Journal of Crohn's and Colitis*, **2019**, 13, S025-S026	1.5	12
318	The day after COVID-19 in IBD: how to go back to 'normal'. *Nature Reviews Gastroenterology and Hepatology*, **2020**, 17, 441-443	24.2	12
317	Ocular symptoms are not predictive of ophthalmologic inflammation in inflammatory bowel disease. *Digestive and Liver Disease*, **2013**, 45, 195-9	3.3	12
316	Letter: addition of methotrexate neither restores clinical response nor improves the pharmacokinetic profile of vedolizumab-treated patients. *Alimentary Pharmacology and Therapeutics*, **2017**, 46, 1019-1020	6.1	12
315	Filgotinib in Crohn's Disease: JAK Is Back. *Gastroenterology*, **2017**, 153, 603-605	13.3	12
314	Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. *The Lancet Gastroenterology and Hepatology*, **2021**,	18.8	12
313	Early Intervention in Ulcerative Colitis: Ready for Prime Time?. *Journal of Clinical Medicine*, **2020**, 9,	5.1	12
312	Accuracy of Diffusion-weighted Magnetic Resonance Colonography in Assessing Mucosal Healing and the Treatment Response in Patients with Ulcerative Colitis. *Journal of Crohn's and Colitis*, **2017**, 11, 716-723	1.5	12
311	Clinical efficacy of the Toll-like receptor 9 agonist cobitolimod using patient-reported-outcomes defined clinical endpoints in patients with ulcerative colitis. *Digestive and Liver Disease*, **2018**, 50, 1019-1029	3.3	12
310	Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients. *Inflammatory Bowel Diseases*, **2019**, 25, 1399-1407	4.5	11
309	Lymphatic endothelium contributes to colorectal cancer growth via the soluble matrisome component GDF11. *International Journal of Cancer*, **2019**, 145, 1913-1920	7.5	11
308	OP01 Higher vs. standard adalimumab maintenance regimens in patients with moderately to severely active ulcerative colitis: Results from the SERENE-UC maintenance study. *Journal of Crohn's and Colitis*, **2020**, 14, S001-S001	1.5	11
307	Positioning Tofacitinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis. *Inflammatory Bowel Diseases*, **2018**, 24, 2106-2112	4.5	11
306	NOD2 gene variant is a risk factor for postoperative complications in patients with Crohn's disease: A genetic association study. *Surgery*, **2016**, 160, 74-80	3.6	11
305	Systematic screening for primary sclerosing cholangitis with magnetic resonance cholangiography in inflammatory bowel disease. *Digestive and Liver Disease*, **2018**, 50, 1012-1018	3.3	11
304	Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab. *Digestive and Liver Disease*, **2014**, 46, 1043-6	3.3	11

303	5-Aminosalicylates and renal function monitoring in inflammatory bowel disease: a nationwide survey. *Journal of Crohn's and Colitis*, **2013**, 7, 551-5	1.5	11
302	Management of patients with inflammatory bowel disease and spondyloarthritis. *Expert Review of Clinical Pharmacology*, **2017**, 10, 1363-1374	3.8	11
301	Cost savings of anti-TNF therapy using a test-based strategy versus an empirical dose escalation in Crohn's disease patients who lose response to infliximab. *Journal of Market Access & Health Policy*, **2015**, 3,	3.7	11
300	Beliefs and behaviour about smoking among inflammatory bowel disease patients. *European Journal of Gastroenterology and Hepatology*, **2015**, 27, 797-803	2.2	11
299	Management of inflammatory bowel disease in France: a nationwide survey among private gastroenterologists. *Digestive and Liver Disease*, **2014**, 46, 675-81	3.3	11
298	Ulcerative colitis as a sole mucosal disease: another misunderstanding?. *Gut*, **2012**, 61, 633	19.2	11
297	Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy-Access to Rapid Treatment (iSTART) approach. *Intestinal Research*, **2018**, 16, 522-528	4.1	11
296	Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis. *Alimentary Pharmacology and Therapeutics*, **2020**, 51, 435-445	6.1	11
295	Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial. *The Lancet Gastroenterology and Hepatology*, **2020**, 5, 1063-1075	18.8	11
294	Treatment Persistence of Infliximab Versus Adalimumab in Ulcerative Colitis: A 16-Year Single-Center Experience. *Inflammatory Bowel Diseases*, **2019**, 25, 945-954	4.5	11
293	Cost savings using a test-based de-escalation strategy for patients with Crohn's disease in remission on optimized infliximab: A discrete event model study. *Digestive and Liver Disease*, **2019**, 51, 112-119	3.3	11
292	Shedding Light on Hemostasis in Patients With Inflammatory Bowel Diseases. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 1088-1097.e6	6.9	11
291	TNF Inhibitors and Risk of Malignancy in Patients with Inflammatory Bowel Diseases: A Systematic Review. *Journal of Crohn's and Colitis*, **2021**, 15, 840-859	1.5	11
290	Azathioprine for refractory ulcerative proctitis: A retrospective multicenter study. *Digestive and Liver Disease*, **2017**, 49, 280-285	3.3	10
289	Impact of inflammatory bowel diseases on working life: A French nationwide survey. *Digestive and Liver Disease*, **2019**, 51, 961-966	3.3	10
288	Anti-TNF biosimilars in Crohn's Disease: a patient-centric interdisciplinary approach. *Expert Review of Gastroenterology and Hepatology*, **2019**, 13, 731-738	4.2	10
287	CARD8 gene variant is a risk factor for recurrent surgery in patients with Crohn's disease. *Digestive and Liver Disease*, **2015**, 47, 938-42	3.3	10
286	Deep remission in Crohn's disease: is it the end of the placebo effect?. *Clinical Gastroenterology and Hepatology*, **2014**, 12, 347	6.9	10

285	Complete Endoscopic Healing Associated With Better Outcomes Than Partial Endoscopic Healing in Patients With Crohn's Disease. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 2256-2261	6.9	10
284	Patients' knowledge and fear of colorectal cancer risk in inflammatory bowel disease. *Journal of Digestive Diseases*, **2016**, 17, 383-91	3.3	10
283	Dose de-escalation to adalimumab 40 mg every three weeks in patients with inflammatory bowel disease-A multicenter, retrospective, observational study. *Digestive and Liver Disease*, **2019**, 51, 236-241	3.3	10
282	A Practical Guide for Faecal Calprotectin Measurement: Myths and Realities. *Journal of Crohn's and Colitis*, **2021**, 15, 152-161	1.5	10
281	IL-17 Inhibitors and Inflammatory Bowel Diseases: A Postmarketing Study in Vigibase. *Clinical Pharmacology and Therapeutics*, **2021**, 110, 159-168	6.1	10
280	Primetime for e-health in IBD?. *Nature Reviews Gastroenterology and Hepatology*, **2017**, 14, 133-134	24.2	9
279	Microbiota in digestive cancers: our new partner?. *Carcinogenesis*, **2017**, 38, 1157-1166	4.6	9
278	Modulation of sphingosine-1-phosphate in ulcerative colitis. *Expert Opinion on Biological Therapy*, **2020**, 20, 413-420	5.4	9
277	Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel Diseases. *Inflammatory Bowel Diseases*, **2016**, 22, 2711-2723	4.5	9
276	Are we improving disease outcomes in IBD? A view from the epidemiology side. *Gut*, **2014**, 63, 1529-30	19.2	9
275	Inflammatory Bowel Disease and COVID-19 Vaccination: A Patients' Survey. *Digestive Diseases and Sciences*, **2021**, 1	4	9
274	Cumulative Length of Bowel Resection in a Population-Based Cohort of Patients With Crohn's Disease. *Clinical Gastroenterology and Hepatology*, **2016**, 14, 1439-44	6.9	9
273	Clinical guidelines for the management of inflammatory bowel disease: Update of a French national consensus. *Digestive and Liver Disease*, **2021**, 53, 35-43	3.3	9
272	Emerging treatment options for extraintestinal manifestations in IBD. *Gut*, **2021**, 70, 796-802	19.2	9
271	25-OH vitamin D level has no impact on the efficacy of antiviral therapy in naïve genotype 1 HCV-infected patients. *United European Gastroenterology Journal*, **2017**, 5, 69-75	5.3	8
270	745 Methotrexate for Corticosteroid-Dependent Ulcerative Colitis: Results of a Placebo Randomized Controlled Trial. *Gastroenterology*, **2015**, 148, S-140	13.3	8
269	The deficit in folate and vitamin B12 triggers liver macrovesicular steatosis and inflammation in rats with dextran sodium sulfate-induced colitis. *Journal of Nutritional Biochemistry*, **2020**, 84, 108415	6.3	8
268	Comparative accuracy of ferritin, transferrin saturation and soluble transferrin receptor for the diagnosis of iron deficiency in inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics*, **2020**, 51, 1087-1095	6.1	8

267	979 Impact of Concomitant Immunomodulator Treatment on Efficacy and Safety of Anti-TNF Therapy in Crohn's Disease: A Meta-Analysis of Placebo Controlled Trials With Individual Patient-Level Data. *Gastroenterology*, **2013**, 144, S-179	13.3	8
266	Adherence to infliximab therapy in inflammatory bowel disease patients in a real-life setting. *Journal of Digestive Diseases*, **2017**, 18, 566-573	3.3	8
265	DOP025 Efficacy of vedolizumab on extraintestinal manifestation in patients with inflammatory bowel disease: a post-hoc analysis of the OBSERV-IBD cohort from the GETAID. *Journal of Crohn's and Colitis*, **2017**, 11, S42-S42	1.5	8
264	IBD: To switch or not to switch: that is the biosimilar question. *Nature Reviews Gastroenterology and Hepatology*, **2017**, 14, 508-509	24.2	8
263	Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials. *Gastroenterology*, **2021**,	13.3	8
262	Maximizing the diagnostic information from biopsies in chronic inflammatory bowel diseases: recommendations from the Erlangen International Consensus Conference on Inflammatory Bowel Diseases and presentation of the IBD-DCA score as a proposal for a new index for histologic activity assessment in ulcerative colitis and Crohn's disease. *Virchows Archiv Fur Pathologische Anatomie*	5.1	8
261	Impact of a medical interview on the decision to switch from originator infliximab to its biosimilar in patients with inflammatory bowel disease. *Digestive and Liver Disease*, **2020**, 52, 281-288	3.3	8
260	Faecal Calprotectin for the Diagnosis of Bowel Inflammation in Patients With Rheumatological Diseases: A Systematic Review. *Journal of Crohn's and Colitis*, **2020**, 14, 688-693	1.5	8
259	Histological healing: should it be considered as a new outcome for ulcerative colitis?. *Expert Opinion on Biological Therapy*, **2020**, 20, 407-412	5.4	8
258	Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise. *Inflammatory Bowel Diseases*, **2021**, 27, 2023-2030	4.5	8
257	Vaccination for influenza and pneumococcus in patients with gastrointestinal cancer or inflammatory bowel disease: A prospective cohort study of methods for improving coverage. *Alimentary Pharmacology and Therapeutics*, **2019**, 49, 84-90	6.1	8
256	Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study. *Journal of Crohn's and Colitis*, **2021**, 15, 950-959	1.5	8
255	A Simplified Definition of Histologic Improvement in Ulcerative Colitis and its Association With Disease Outcomes up to 30 Weeks from Initiation of Therapy: Post Hoc Analysis of Three Clinical Trials. *Journal of Crohn's and Colitis*, **2019**, 13, 1025-1035	1.5	7
254	Prolonged azathioprine treatment reduces the need for surgery in early Crohn's disease. *Journal of Gastroenterology and Hepatology (Australia)*, **2018**, 33, 664-670	4	7
253	Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study. *BMJ Open Gastroenterology*, **2016**, 3, e000092	3.9	7
252	Pharmacokinetics of Infliximab and Reduction of Treatment for Inflammatory Bowel Diseases. *Digestive Diseases and Sciences*, **2016**, 61, 990-5	4	7
251	Self-medication with steroids in inflammatory bowel disease. *Digestive and Liver Disease*, **2016**, 48, 23-6	3.3	7
250	Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis?. *Baillière's Best Practice and Research in Clinical Gastroenterology*, **2018**, 32-33, 17-25	2.5	7

249	Tolerability of one hour 10 mg/kg infliximab infusions in patients with inflammatory bowel disease. *Journal of Crohn's and Colitis*, **2013**, 7, 129-33	1.5	7
248	Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. *The Lancet Gastroenterology and Hepatology*, **2021**,	18.8	7
247	Early changes in the pharmacokinetic profile of vedolizumab-treated patients with IBD may predict response after dose optimisation. *Gut*, **2019**, 68, 178-179	19.2	7
246	Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 620-627.e1	6.9	7
245	Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing Crohn's Disease: ENTERPRISE Study. *Clinical Gastroenterology and Hepatology*, **2021**,	6.9	7
244	Efficacy, Tolerability, and Safety of Low-Volume Bowel Preparations for Patients with Inflammatory Bowel Diseases: The French Multicentre CLEAN Study. *Journal of Crohn's and Colitis*, **2019**, 13, 1121-1130	1.5	6
243	Keratoconus in Inflammatory Bowel Disease Patients: A Cross-sectional Study. *Journal of Crohn's and Colitis*, **2015**, 9, 1108-12	1.5	6
242	Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block. *Expert Opinion on Biological Therapy*, **2020**, 20, 421-427	5.4	6
241	Genomic and molecular alterations in human inflammatory bowel disease-associated colorectal cancer. *United European Gastroenterology Journal*, **2020**, 8, 675-684	5.3	6
240	Vedolizumab for the treatment of Crohn's disease. *Expert Review of Clinical Immunology*, **2018**, 14, 179-189	3.2	6
239	mTOR-Dependent Stimulation of Orchestrates Immune Cell Trafficking through Lymphatic Endothelium in Patients with Crohn's Disease. *Cells*, **2019**, 8,	7.9	6
238	Tofacitinib Is the Right OCTAVE for Ulcerative Colitis. *Gastroenterology*, **2017**, 153, 862-864	13.3	6
237	Implementing the Concept of Continuous Clinical Response Into Clinical Practice for Ulcerative Colitis. *Clinical Gastroenterology and Hepatology*, **2017**, 15, 1154-1161.e1	6.9	6
236	Plasma soluble triggering receptor expressed on myeloid cells-1 in Crohn's disease. *Digestive and Liver Disease*, **2012**, 44, 466-70	3.3	6
235	Stopping infliximab in Crohn's disease: still an ongoing STORI. *Inflammatory Bowel Diseases*, **2012**, 18, 2201-2	4.5	6
234	Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?. *Current Pharmaceutical Design*, **2019**, 25, 7-12	3.3	6
233	Bowel damage assessment in Crohn's disease by magnetic resonance imaging. *Current Drug Targets* , **2012**, 13, 1300-7	3	6
232	Long-term safety of approved biologics for ulcerative colitis. *Expert Opinion on Drug Safety*, **2020**, 19, 807-816	4.1	6

231	Herpes Zoster and Vaccination Strategies in Inflammatory Bowel Diseases: A Practical Guide. *Clinical Gastroenterology and Hepatology*, **2020**,	6.9	6
230	Thiopurines' Metabolites and Drug Toxicity: A Meta-Analysis. *Journal of Clinical Medicine*, **2020**, 9,	5.1	6
229	New drugs in the pipeline for the treatment of inflammatory bowel diseases: what is coming?. *Current Opinion in Pharmacology*, **2020**, 55, 141-150	5.1	6
228	Setting up a Virtual Calprotectin Clinic in Inflammatory Bowel Diseases: Literature Review and Nancy Experience. *Journal of Clinical Medicine*, **2020**, 9,	5.1	6
227	Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis. *Journal of Clinical Medicine*, **2020**, 9,	5.1	6
226	International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases. *United European Gastroenterology Journal*, **2021**, 9, 451-460	5.2	6
225	A Magnetic Resonance Imaging Index to Predict Crohn's Disease Postoperative Recurrence: The MONITOR Index. *Clinical Gastroenterology and Hepatology*, **2021**,	6.9	6
224	Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease. *Inflammatory Bowel Diseases*, **2021**, 27, 106-122	4.5	6
223	Evolution of Endoscopic Lesions in Steroid-Refractory Acute Severe Ulcerative Colitis Responding to Infliximab or Cyclosporine. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 1180-1188.e4	6.9	6
222	Point-of-Care Ultrasound in Inflammatory Bowel Disease. *Journal of Crohn's and Colitis*, **2021**, 15, 143-151	1.5	6
221	An Anti-migration Self-expandable and Removable Metal Stent for Crohn's Disease Strictures: A Nationwide Study From GETAID and SFED. *Journal of Crohn's and Colitis*, **2021**, 15, 521-528	1.5	6
220	Characteristics of Lymphoma in Patients with Inflammatory Bowel Disease: A Systematic Review. *Journal of Crohn's and Colitis*, **2021**, 15, 827-839	1.5	6
219	Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters. *MAbs*, **2021**, 13, 1868078	6.6	6
218	Transmural healing as a therapeutic goal in Crohn's disease: a systematic review. *The Lancet Gastroenterology and Hepatology*, **2021**, 6, 659-667	18.8	6
217	Interleukin-23 Blockers: Born to be First-line Biologic Agents in Inflammatory Bowel Disease?. *Current Pharmaceutical Design*, **2019**, 25, 25-31	3.3	5
216	Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13. *Expert Review of Gastroenterology and Hepatology*, **2015**, 9 Suppl 1, 5-15	4.2	5
215	Emerging therapies for the treatment of ulcerative colitis. *Expert Opinion on Emerging Drugs*, **2020**, 1-9	3.7	5
214	Infliximab biosimilar CT-P13 for inflammatory bowel disease. *The Lancet Gastroenterology and Hepatology*, **2018**, 3, 373-375	18.8	5

213	Head-to-head Comparative Studies: Challenges and Opportunities?. *Journal of Crohn's and Colitis*, **2017**, 11, S567-S575	1.5	5
212	Post-operative complications in elderly onset inflammatory bowel disease: a population-based study. *Alimentary Pharmacology and Therapeutics*, **2018**, 47, 1652-1660	6.1	5
211	A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®) for active, mild-to-moderate ulcerative colitis. *United European Gastroenterology Journal*, **2019**, 7, 1171-1182	5.3	5
210	Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis. *British Journal of Clinical Pharmacology*, **2019**, 85, 2244-2254	3.8	5
209	IBD in 2013: enriching the therapeutic armamentarium for IBD. *Nature Reviews Gastroenterology and Hepatology*, **2014**, 11, 84-6	24.2	5
208	Azathioprine in early Crohn's disease: time to revisit patient selection and end points for clinical trials and/or azathioprine efficacy?. *Gastroenterology*, **2014**, 146, 867-8	13.3	5
207	Location but Not Severity of Endoscopic Lesions Influences Endoscopic Remission Rates in Crohn's Disease: A Post Hoc Analysis of TAILORIX. *American Journal of Gastroenterology*, **2021**, 116, 134-141	0.7	5
206	Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. *The Lancet Gastroenterology and Hepatology*, **2021**,	18.8	5
205	Oral Iron for IBD Patients: Lessons Learned at Time of COVID-19 Pandemic. *Journal of Clinical Medicine*, **2020**, 9,	5.1	5
204	Evolving therapeutic goals in Crohn's disease management. *United European Gastroenterology Journal*, **2020**, 8, 133-139	5.3	5
203	Validation of the Red Flags Index for Early Diagnosis of Crohn's Disease: A Prospective Observational IG-IBD Study Among General Practitioners. *Journal of Crohn's and Colitis*, **2020**,	1.5	5
202	Low Back Pain and Sacroiliitis on Cross-Sectional Abdominal Imaging for Axial Spondyloarthritis Diagnosis in Inflammatory Bowel Diseases. *Inflammatory Intestinal Diseases*, **2020**, 5, 124-131	2.5	5
201	Treat to target or 'treat to clear' in inflammatory bowel diseases: one step further?. *Expert Review of Gastroenterology and Hepatology*, **2020**, 14, 807-817	4.2	5
200	Assessment of extraintestinal manifestations in inflammatory bowel diseases: A systematic review and a proposed guide for clinical trials. *United European Gastroenterology Journal*, **2020**, 8, 1013-1030	5.3	5
199	Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis. *Clinical Gastroenterology and Hepatology*, **2020**,	6.9	5
198	Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice. *Expert Review of Clinical Immunology*, **2020**, 16, 1019-1028	5.1	5
197	A17 EFFICACY AND SAFETY OF FILGOTINIB AS MAINTENANCE THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY. *Journal of the Canadian Association of Gastroenterology*, **2021**, 4, 21-23	0.5	5
196	Environmental, Nutritional, and Socioeconomic Determinants of IBD Incidence: A Global Ecological Study. *Journal of Crohn's and Colitis*, **2020**, 14, 323-331	1.5	5

195	A Global, Prospective, Observational Study Measuring Disease Burden and Suffering in Patients with Ulcerative Colitis Using the Pictorial Representation of Illness and Self-Measure Tool. *Journal of Crohn's and Colitis*, **2020**,	1.5	5
194	The Brain-Gut Axis: Psychological Functioning and Inflammatory Bowel Diseases. *Journal of Clinical Medicine*, **2021**, 10,	5.1	5
193	Calorie Restriction as a New Treatment of Inflammatory Diseases. *Advances in Nutrition*, **2021**, 12, 1558-1570	10	5
192	International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. *Nature Reviews Gastroenterology and Hepatology*, **2021**, 18, 857-873	24.2	5
191	Detection and management of early stage inflammatory bowel disease: an update for clinicians. *Expert Review of Gastroenterology and Hepatology*, **2019**, 13, 547-555	4.2	4
190	Targeting SMAD7 in Crohn's Disease by Mongersen: Therapeutic Revolution Under Way?. *Gastroenterology*, **2015**, 149, 1121-3	13.3	4
189	Targeting the gut layers in Crohn's disease: mucosal or transmural healing?. *Expert Review of Gastroenterology and Hepatology*, **2020**, 14, 775-787	4.2	4
188	Clinical Trials for Inflammatory Bowel Disease: Global Guidance During the COVID-19 Pandemic. *Journal of Crohn's and Colitis*, **2020**, 14, S815-S819	1.5	4
187	Statins and inflammatory bowel disease: Where do we stand?. *European Journal of Internal Medicine* , **2020**, 75, 10-14	3.9	4
186	DOP13 Clinical and endoscopic response to ustekinumab in Crohn disease: Week 16 interim analysis of the STARDUST trial. *Journal of Crohn's and Colitis*, **2020**, 14, S049-S052	1.5	4
185	Pharmacological Prevention of Postoperative Recurrence in Crohn's Disease. *Drugs*, **2020**, 80, 385-399	12.1	4
184	Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort Study. *Journal of Crohn's and Colitis*, **2020**, 14, 896-903	1.5	4
183	Efficacy of anti-TNF drugs in patients with stricturing Crohn's disease. *Expert Review of Gastroenterology and Hepatology*, **2020**, 14, 347-353	4.2	4
182	P573 Safety and immune modulatory properties of etrasimod (APD334), a next-generation oral, selective sphingosine 1-phosphate receptor (S1PR) modulator, in healthy volunteers. *Journal of Crohn's and Colitis*, **2018**, 12, S397-S397	1.5	4
181	Physicians' perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey. *Alimentary Pharmacology and Therapeutics*, **2018**, 47, 773-783	6.1	4
180	Is Diffusion-weighted Magnetic Resonance Imaging for Assessing Crohn's Disease Ready for Prime Time? Experience with the Nancy Score. *Inflammatory Bowel Diseases*, **2015**, 21, E25	4.5	4
179	A snapshot of the ongoing clinical research on COVID-19. *F1000Research*, **2020**, 9, 373	3.6	4
178	Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives.. *The Lancet Gastroenterology and Hepatology*, **2022**, 7, 171-185	18.8	4

177	Histologically confirmed upper gastrointestinal Crohn's disease: is it rare or are we just not searching hard enough?. *Intestinal Research*, **2020**, 18, 210-218	4.1	4
176	Is there a role for therapeutic sphingolipids in inflammatory bowel disease?. *Expert Review of Gastroenterology and Hepatology*, **2020**, 14, 47-54	4.2	4
175	Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status. *Clinical Gastroenterology and Hepatology*, **2021**,	6.9	4
174	A15 EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY. *Journal of the Canadian Association of Gastroenterology*, **2021**, 4, 18-20	0.5	4
173	Safety of S1P Modulators in Patients with Immune-Mediated Diseases: A Systematic Review and Meta-Analysis. *Drug Safety*, **2021**, 44, 645-660	5.1	4
172	Validation of the 'Inflammatory Bowel Disease-Distribution, Chronicity, Activity [IBD-DCA] Score' for Ulcerative Colitis and Crohn's Disease. *Journal of Crohn's and Colitis*, **2021**, 15, 1621-1630	1.5	4
171	Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease. *United European Gastroenterology Journal*, **2021**, 9, 552-560	5.3	4
170	Efficacy of biological drugs in short-duration versus long-duration inflammatory bowel disease: a protocol for a systematic review and an individual-patient level meta-analysis of randomised controlled trials. *BMJ Open*, **2019**, 9, e024222	3	4
169	Risk of Late Postoperative Recurrence of Crohn's Disease in Patients in Endoscopic Remission After Ileocecal Resection, Over 10 Years at Multiple Centers. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 1218-1225.e4	6.9	4
168	Milan ultrasound criteria are accurate in assessing disease activity in ulcerative colitis: external validation. *United European Gastroenterology Journal*, **2021**, 9, 438-442	5.3	4
167	Sa1812 Endoscopic and Deep Remission At 1 Year Prevents Disease Progression in Early Crohn's Disease: Long-Term Data from Calm. *Gastroenterology*, **2019**, 156, S-411	13.3	3
166	Cost-of-illness of inflammatory bowel disease patients treated with anti-tumour necrosis factor: A French large single-centre experience. *United European Gastroenterology Journal*, **2019**, 7, 908-913	5.3	3
165	Challenges and opportunities for IBD drug development: from early stage to regulatory approval. *Gut*, **2020**, 69, 1157-1161	19.2	3
164	Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins?. *Expert Opinion on Biological Therapy*, **2020**, 20, 353-361	5.4	3
163	Transmural Histological Scoring Systems in Crohn's Disease: A Systematic Review With Assessment of Methodological Quality and Operating Properties. *Journal of Crohn's and Colitis*, **2020**, 14, 743-756	1.5	3
162	Treatment Adherence in Inflammatory Bowel Disease Patients from Argentina: A Multicenter Study. *Gastroenterology Research and Practice*, **2020**, 2020, 4060648	2	3
161	Early Combined Immunosuppression in Crohn's Disease: Acting Rather Than REACTing. *Gastroenterology*, **2016**, 150, 1040-1	13.3	3
160	Can elderly people be treated safely with anti-TNF agents?. *Inflammatory Bowel Diseases*, **2012**, 18, 594-5	4.5	3

159	DOP078 Pharmacology and safety of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulator. *Journal of Crohn's and Colitis*, **2017**, 11, S72-S72	1.5	3
158	Clinical remission as defined by the Mayo Score: do we deceive ourselves?. *Inflammatory Bowel Diseases*, **2015**, 21, E2-3	4.5	3
157	The POCER Trial: Bet on Active Care. *Gastroenterology*, **2015**, 148, 1474-5	13.3	3
156	Ustekinumab in Crohn's Disease: New Data for Positioning in Treatment Algorithm.. *Journal of Crohn's and Colitis*, **2022**, 16, ii30-ii41	1.5	3
155	Higher vs Standard Adalimumab Induction Dosing Regimens and 2 Maintenance Strategies: Randomized SERENE CD Trial Results.. *Gastroenterology*, **2022**,	13.3	3
154	Steroid-Free Deep Remission At One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial. *Clinical Gastroenterology and Hepatology*, **2021**,	6.9	3
153	Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues.. *Therapeutic Advances in Gastroenterology*, **2021**, 14, 17562848211059954	4.7	3
152	Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?. *Drugs*, **2021**, 81, 1859-1879	10.1	3
151	Patient's profiling for therapeutic management of inflammatory bowel disease: a tailored approach. *Expert Review of Gastroenterology and Hepatology*, **2020**, 14, 765-773	4.2	3
150	Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design. *Gastroenterology*, **2020**, 159, 2013-2018.e7	13.3	3
149	Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus. *Autoimmunity Reviews*, **2021**, 20, 102849	13.6	3
148	Early Intervention With Vedolizumab on Longer Term Surgery Rates in Crohn's Disease: Post Hoc Analysis of the GEMINI Phase 3 and Long-term Safety Programs. *Journal of Crohn's and Colitis*, **2020**,	1.5	3
147	Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13. *Expert Opinion on Biological Therapy*, **2021**, 21, 37-46	5.4	3
146	Nocebo effect and biosimilars in inflammatory bowel diseases: what's new and what's next?. *Expert Opinion on Biological Therapy*, **2021**, 21, 47-55	5.4	3
145	An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials. *Alimentary Pharmacology and Therapeutics*, **2021**, 53, 784-793	6.1	3
144	Endpoints for Perianal Crohn's Disease Trials: Past, Present and Future. *Journal of Crohn's and Colitis*, **2021**, 15, 1387-1398	1.5	3
143	Incidence of and Risk Factors for Colorectal Strictures in Ulcerative Colitis: A Multicenter Study. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 1899-1905.e1	6.9	3
142	Sugars and Gastrointestinal Health.. *Clinical Gastroenterology and Hepatology*, **2021**,	6.9	3

141	No Excess Cancer Recurrence After Immunosuppressive Drugs in a Meta-analysis of Cohorts of Patients With Immune-mediated Diseases: A Mirage Related to Propensity Bias?. *Gastroenterology*, **2017**, 152, 304-306	13.3	2
140	DOP71 Effects of ustekinumab induction therapy on endoscopic and histological healing in the UNIFI Phase 3 study in ulcerative colitis. *Journal of Crohn's and Colitis*, **2019**, 13, S073-S073	1.5	2
139	Vedolizumab for the treatment of inflammatory bowel diseases: from symptomatic control to mucosal healing. *Immunotherapy*, **2019**, 11, 565-575	3.8	2
138	Monitoring of inflammatory bowel disease in 2019: A French consensus for clinical practice. *Digestive and Liver Disease*, **2020**, 52, 704-720	3.3	2
137	Clinical Research and Trials-A "Nonessential" Victim of the COVID-19 Pandemic?. *American Journal of Gastroenterology*, **2020**, 115, 946-947	0.7	2
136	PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD. *Expert Review of Gastroenterology and Hepatology*, **2020**, 14, 797-806	4.2	2
135	Which MRI Score and Technique Should Be Used for Assessing Crohn's Disease Activity?. *Journal of Clinical Medicine*, **2020**, 9,	5.1	2
134	JAK or GUT Selectivity: Tipping the Balance for Efficacy and Safety in Ulcerative Colitis. *Journal of Crohn's and Colitis*, **2020**, 14, 1185-1187	1.5	2
133	Telehealth in Inflammatory Bowel Disease: Every Patient May Need a Coach!. *Gastroenterology*, **2018**, 154, 1196-1198	13.3	2
132	Biologic Therapies in Ulcerative Colitis: Primi Inter Pares?. *Current Drug Targets*, **2018**, 19, 748-756	3	2
131	DOP001 Effectiveness and safety of vedolizumab in anti-TNF naïve patients with inflammatory bowel disease: a multicentre retrospective European Crohn's and Colitis Organisation study. *Journal of Crohn's and Colitis*, **2018**, 12, S029-S030	1.5	2
130	Value of cross-sectional imaging in assessing active Crohn's disease before stoma reversal. *Digestive and Liver Disease*, **2017**, 49, 864-871	3.3	2
129	P369 Safety and lymphocyte-lowering properties of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulator, after dose escalation in healthy volunteers. *Journal of Crohn's and Colitis*, **2017**, 11, S265-S266	1.5	2
128	Predicting future disease course in Crohn's disease by colonoscopy or magnetic resonance: which is the crystal ball?. *Gut*, **2015**, 64, 1347-8	19.2	2
127	Long-Term Overconsumption of Fat and Sugar Causes a Partially Reversible Pre-inflammatory Bowel Disease State. *Frontiers in Nutrition*, **2021**, 8, 758518	6.2	2
126	Kidney function monitoring in inflammatory bowel disease: The MONITORED consensus. *Digestive and Liver Disease*, **2021**,	3.3	2
125	Anti-fibrotic Drugs for Crohn's Disease: Ready for Prime Time?. *Current Pharmaceutical Design*, **2019**, 25, 47-56	3.3	2
124	'Treat to Target' in Mild to Moderate Ulcerative Colitis: Evidence to Support this Strategy. *Current Drug Targets*, **2021**, 22, 117-125	3	2

123	Evolving Treatment Algorithms in Crohn's Disease. *Current Drug Targets*, **2018**, 19, 782-790	3	2
122	Efficacy and Safety of Ustekinumab as Maintenance Therapy in Ulcerative Colitis: Week 44 Results from UNIFI **2019**, 57,		2
121	Evolving primary and secondary endpoints in randomized controlled trials leading to approval of biologics and small molecules in IBD: an historical perspective. *Expert Opinion on Biological Therapy*, **2020**, 20, 151-161	5.4	2
120	Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 2567-2576.e9	6.9	2
119	Endoscopic balloon dilation of colorectal strictures complicating Crohn's disease: a multicenter study. *Clinics and Research in Hepatology and Gastroenterology*, **2021**, 45, 101561	2.4	2
118	Tools for fecal incontinence assessment: lessons for inflammatory bowel disease trials based on a systematic review. *United European Gastroenterology Journal*, **2020**, 8, 886-922	5.3	2
117	Long-term outcome of Crohn's disease patients with upper gastrointestinal stricture: A GETAID study. *Digestive and Liver Disease*, **2020**, 52, 1323-1330	3.3	2
116	Probe-based Confocal Laser Endomicroscopy for In Vivo Assessment of Histological Healing in Ulcerative Colitis: Development and Validation of the ENHANCE Index. *Journal of Crohn's and Colitis*, **2021**, 15, 994-999	1.5	2
115	Predictive Value of Bowel Ultrasound in Crohn's Disease: A 12-Month Prospective Study. *Clinical Gastroenterology and Hepatology*, **2021**,	6.9	2
114	Histological Disease Activity Measured by the Nancy Index Is Associated with Long-term Outcomes in Patients with Ulcerative Colitis. *Journal of Crohn's and Colitis*, **2021**, 15, 1631-1640	1.5	2
113	Kidney function monitoring to prevent 5-aminosalicylic acid nephrotoxicity: What the gastroenterologist should know. *Digestive and Liver Disease*, **2021**, 53, 691-696	3.3	2
112	Defining difficult-to-treat inflammatory bowel disease: why and how. *The Lancet Gastroenterology and Hepatology*, **2021**, 6, 520-522	18.8	2
111	The Crohn's Disease-Ulcerative Colitis Clinical Appraisal Update: Emerging Trends in Clinical Practice. *Clinical Gastroenterology and Hepatology*, **2016**, 14, e121-2	6.9	2
110	Time to include patients with ulcerative proctitis in clinical trials. *The Lancet Gastroenterology and Hepatology*, **2019**, 4, 900-902	18.8	2
109	Crohn's Disease Only Visible on Small Bowel Capsule Endoscopy: A New Entity. *Digestive Diseases and Sciences*, **2021**, 66, 2712-2716	4	2
108	Application of Ultrasound Elastography for Assessing Intestinal Fibrosis in Inflammatory Bowel Disease: Fiction or Reality?. *Current Drug Targets*, **2021**, 22, 347-355	3	2
107	Ulcerative Colitis Narrative Global Survey Findings: The Impact of Living With Ulcerative Colitis-Patients' and Physicians' View. *Inflammatory Bowel Diseases*, **2021**, 27, 1747-1755	4.5	2
106	Anti-TNF therapy for genital fistulas in female patients with Crohn's disease: a nationwide study from the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID). *Alimentary Pharmacology and Therapeutics*, **2018**, 48, 831-838	6.1	2

105	Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study. *Alimentary Pharmacology and Therapeutics*, **2021**, 54, 944-951	6.1	2
104	Viral infections in inflammatory bowel disease: Tips and tricks for correct management. *World Journal of Gastroenterology*, **2021**, 27, 4276-4297	5.6	2
103	Gastroenterological safety of IL-17 inhibitors: a systematic literature review. *Expert Opinion on Drug Safety*, **2021**, 1-17	4.1	2
102	Telomeres: New players in immune-mediated inflammatory diseases?. *Journal of Autoimmunity*, **2021**, 123, 102699	15.5	2
101	Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY). *Gastroenterology*, **2021**, 161, 1156-1167.e3	13.3	2
100	Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results.. *Gastroenterology*, **2022**,	13.3	2
99	Personalised medicine in inflammatory bowel diseases: a patient survey. *Scandinavian Journal of Gastroenterology*, **2019**, 54, 135	2.4	1
98	P312 Efficacy in biologic failure and non-biologic-failure populations in a Phase 3 study of ustekinumab in moderate□severe ulcerative colitis: UNIFI. *Journal of Crohn's and Colitis*, **2019**, 13, S256-S257	1.5	1
97	Effectiveness of Infliximab Biosimilar in Crohn's Disease: A Dime, A Dozen. *Gastroenterology*, **2019**, 156, 2349-2351	13.3	1
96	Flare-IBD: development and validation of a questionnaire based on patients' messages on an internet forum for early detection of flare in inflammatory bowel disease: study protocol. *BMJ Open*, **2020**, 10, e037211	3	1
95	Surgery for Crohn's disease during pregnancy: A nationwide survey. *United European Gastroenterology Journal*, **2020**, 8, 736-740	5.3	1
94	An index with improved diagnostic accuracy for the diagnosis of Crohn's disease derived from the Lennard-Jones criteria. *Alimentary Pharmacology and Therapeutics*, **2016**, 44, 601-11	6.1	1
93	Implementation of the French national consensus for the management of ulcerative colitis into clinical practice. *Digestive and Liver Disease*, **2016**, 48, 1405-1409	3.3	1
92	Immunomodulators for the treatment of Crohn's disease in adults: optimal use and prospects for future drug treatments. *Expert Review of Clinical Immunology*, **2016**, 12, 741-9	5.1	1
91	Ileal ulcers not responding to infliximab therapy: think about intestinal ganglioneuromatosis. *Digestive and Liver Disease*, **2015**, 47, 257-8	3.3	1
90	Complementary and alternative medicine in inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics*, **2012**, 35, 619-20	6.1	1
89	Knowledge of 5-aminosalicylic acid nephrotoxicity and adherence to kidney function monitoring of patients with inflammatory bowel disease. *European Journal of Gastroenterology and Hepatology*, **2021**, 33, 1148-1152	2.2	1
88	Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era.. *Advances in Therapy*, **2022**, 1	4.1	1

87	Letter: treatment with subcutaneous CT-P13 in Crohn's disease patients with intravenous infliximab failure.. *Alimentary Pharmacology and Therapeutics*, **2022**, 55, 508-509	6.1	1
86	P230 Ultrasonography-based and Magnetic Resonance-based Lémann Index: two sides of the same coin. *Journal of Crohn's and Colitis*, **2022**, 16, i278-i279	1.5	1
85	Thiopurines and non-melanoma skin cancer: partners in crime in inflammatory bowel diseases. *British Medical Bulletin*, **2020**, 136, 107-117	5.4	1
84	Magnetic Resonance Elastography for Assessing Fibrosis in Patients with Crohn's Disease: A Pilot Study. *Digestive Diseases and Sciences*, **2021**, 1	4	1
83	Evolving short- and long-term goals of management of IBD: getting it right, making it last.. *Gastroenterology*, **2021**,	13.3	1
82	Anti-adhesion Molecules in IBD: Does Gut Selectivity Really Make the Difference?. *Current Pharmaceutical Design*, **2019**, 25, 19-24	3.3	1
81	Bariatric Surgery in Patients With Inflammatory Bowel Disease: A Case-Control Study from the GETAID. *Inflammatory Bowel Diseases*, **2021**,	4.5	1
80	Thrombosis in IBD in the Era of JAK Inhibition. *Current Drug Targets*, **2021**, 22, 126-136	3	1
79	Impact of Treatment-Related Beliefs on Medication Adherence in Immune-Mediated Inflammatory Diseases: Results of the Global ALIGN Study **2017**, 34, 91		1
78	Impact of HIV Infection on the Course of Inflammatory Bowel Disease and Drug Safety Profile: A Multicenter GETAID Study. *Clinical Gastroenterology and Hepatology*, **2020**,	6.9	1
77	Effects of Ustekinumab Induction Therapy on Endoscopic and Histologic Healing in the UNIFI Phase 3 Study in Ulcerative Colitis **2019**, 57,		1
76	The IBD-disk Is a Reliable Tool to Assess the Daily-life Burden of Patients with Inflammatory Bowel Disease. *Journal of Crohn's and Colitis*, **2021**, 15, 766-773	1.5	1
75	Phase I, II and III Trials in Inflammatory Bowel Diseases: A Practical Guide for the Non-specialist. *Journal of Crohn's and Colitis*, **2020**, 14, 710-718	1.5	1
74	Reply. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 3055	6.9	1
73	Predictors for short bowel syndrome in Crohn's disease. *Digestive and Liver Disease*, **2020**, 52, 1455-1460	3.3	1
72	Real-life pilot study on the impact of the telemedicine platform EasyMICI-MaMICI on quality of life and quality of care in patients with inflammatory bowel disease. *Scandinavian Journal of Gastroenterology*, **2021**, 56, 530-536	2.4	1
71	Drug development for ulcerative proctitis: current concepts. *Gut*, **2021**, 70, 1203-1209	19.2	1
70	Quality of Life and Work Productivity Improvements with Upadacitinib: Phase 2b Evidence from Patients with Moderate to Severe Crohn's Disease. *Advances in Therapy*, **2021**, 38, 2339-2352	4.1	1

69	P301 Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: results up to Week 48 of the STARDUST trial. *Journal of Crohn's and Colitis*, **2021**, 15, S330-S331	1.5	1
68	Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort. *Alimentary Pharmacology and Therapeutics*, **2021**, 54, 312-319	6.1	1
67	Letter: histological assessment of disease activity in ulcerative colitis--the problem of score evaluation and validation; authors' reply. *Alimentary Pharmacology and Therapeutics*, **2016**, 43, 439	6.1	1
66	Will COVID-19 Infection be Less Severe in Ulcerative Colitis Than in Crohn's Patients, Due to a Lower Rate of Smokers?. *Journal of Crohn's and Colitis*, **2020**, 14, 1648	1.5	1
65	Clinical, Endoscopic and Histological Outcomes in Induction of Moderate-to-Severe Ulcerative Colitis: A Systematic Review with Meta-Analysis. *Journal of Crohn's and Colitis*, **2021**, 15, 551-566	1.5	1
64	polymorphisms (P268S, IVS8, G908R, L1007fs, R702W) among Kuwaiti patients with Crohn's disease: A case-control study. *Saudi Journal of Gastroenterology*, **2021**, 27, 249-256	3	1
63	Meta-Analysis of the Association Between Anti-Tumour Necrosis Factor Use and Lymphoma Risk in Patients With Inflammatory Bowel Disease: Methodological Considerations. *Journal of Crohn's and Colitis*, **2018**, 12, 1257-1258	1.5	1
62	Challenges and Opportunities in IBD Clinical Trial Design. *Gastroenterology*, **2021**, 161, 400-404	13.3	1
61	Rediscovering histology: what is new in endoscopy for inflammatory bowel disease?. *Therapeutic Advances in Gastroenterology*, **2021**, 14, 17562848211005692	4.7	1
60	Predictive value of Milan ultrasound criteria in ulcerative colitis: A prospective observational cohort study.. *United European Gastroenterology Journal*, **2022**,	5.3	1
59	Difficult-to-treat inflammatory bowel disease: results from a global IOIBD survey.. *The Lancet Gastroenterology and Hepatology*, **2022**, 7, 390-391	18.8	1
58	Composite outcomes in observational studies of ulcerative colitis: A systematic review and meta-analysis.. *United European Gastroenterology Journal*, **2021**,	5.3	1
57	Determinants of IBD-related disability: a cross-sectional survey from the GETAID. *Alimentary Pharmacology and Therapeutics*, **2021**, 53, 1098-1107	6.1	1
56	Is it time to include older adults in inflammatory bowel disease trials? A call for action. *The Lancet Healthy Longevity*, **2022**, 3, e356-e366	9.5	1
55	Psychological Functioning of Patients With Inflammatory Bowel Disease. *Inflammatory Bowel Diseases*, **2019**, 25, e112	4.5	0
54	Management of Inflammatory Bowel Diseases: Clinical Perspectives. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 1249-1251	6.9	0
53	Leukoapheresis in Crohn's disease: the final curtain?. *Gut*, **2013**, 62, 487-8	19.2	0
52	OP39 Shorter disease duration is associated with better outcomes in patients with moderately to severely active Crohn's Disease treated with risankizumab: Results from the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies. *Journal of Crohn's and Colitis*, **2022**, 16, i045-i048	1.5	0

51	OP07 Exploring disease control by combining clinical, biological, and health-related quality of life remission with endoscopic improvements among Ulcerative Colitis patients treated with filgotinib: A post-hoc analysis from the SELECTION trial. *Journal of Crohn's and Colitis*, **2022**, 16, i007-i008	1.5	0
50	P521 Correlation of histological assessment of mucosal healing with long-term clinical and patient-reported outcomes in patients with moderately to severely active ulcerative colitis treated with upadacitinib: results from the Phase 3 U-ACHIEVE maintenance trial. *Journal of Crohn's and Colitis*, **2022**, 16, i471-i472	1.5	0
49	P491 Efficacy and safety outcomes of long-term treatment with filgotinib 200 mg among patients with Ulcerative Colitis: An interim analysis of SELECTIONLTE. *Journal of Crohn's and Colitis*, **2022**, 16, i456-i457	1.5	0
48	P517 Re-treatment with filgotinib in patients with Ulcerative Colitis following treatment interruption: Analysis of the SELECTION and SELECTIONLTE studies. *Journal of Crohn's and Colitis*, **2022**, 16, i473-i474	1.5	0
47	Ethnic Differences in the Smoking-related Risk of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. *Journal of Crohn's and Colitis*, **2021**, 15, 1658-1678	1.5	0
46	P383 Relationship between histo-endoscopic mucosal healing and baseline characteristics in patients with moderately to severely active Ulcerative Colitis receiving filgotinib in the phase 2b/3 SELECTION study. *Journal of Crohn's and Colitis*, **2021**, 15, S395-S396	1.5	0
45	DOP87 Disease clearance as a new therapeutic target in patients with Ulcerative Colitis: A multicenter retrospective cohort study. *Journal of Crohn's and Colitis*, **2021**, 15, S118-S119	1.5	0
44	OP36 Risankizumab therapy induces improvements in endoscopic endpoints in patients with Moderate-to-Severe Crohn Disease: Results from the phase 3 ADVANCE and MOTIVATE studies. *Journal of Crohn's and Colitis*, **2021**, 15, S033-S034	1.5	0
43	Role of Cross-Sectional Imaging in Pediatric Inflammatory Bowel Disease. *Digestive Diseases and Sciences*, **2021**, 1	4	0
42	IBD goes home: from telemedicine to self-administered advanced therapies. *Expert Opinion on Biological Therapy*, **2021**, 1-13	5.4	0
41	Thiopurines: Use them or lose them? International survey on current and future use of thiopurines in inflammatory bowel disease. *Digestive and Liver Disease*, **2021**, 53, 1571-1579	3.3	0
40	Biosimilar knowledge and viewpoints among Brazilian inflammatory bowel disease patients. *Therapeutic Advances in Gastroenterology*, **2021**, 14, 17562848211013249	4.7	0
39	Prevalence of Self-Reported Venous Thromboembolism and Cardiovascular Risk Factors in Patients with Ulcerative Colitis: The GETAID FOCUS Study.. *Digestive Diseases and Sciences*, **2022**, 1	4	0
38	Iron Deficiency in Patients with Inflammatory Bowel Diseases: A Prospective Multicenter Cross-Sectional Study.. *Digestive Diseases and Sciences*, **2022**, 1	4	0
37	Confounding and bias in observational studies in inflammatory bowel disease: a meta-epidemiological study. *Alimentary Pharmacology and Therapeutics*, **2021**, 53, 712-721	6.1	0
36	P400 Discordance in patient and physician perspectives and priorities in communication and management of ulcerative colitis: results of the European ulcerative colitis narrative survey. *Journal of Crohn's and Colitis*, **2019**, 13, S308-S308	1.5	
35	Motivation to pursue anti-TNF treatment in patients with Crohn's disease - the SPACE motivation study. *Digestive and Liver Disease*, **2020**, 52, 995-1001	3.3	
34	P671 Calprotectin does not add accuracy to PRO2 for prediction of continuous clinical response in moderate-to-severe ulcerative colitis patients treated with golimumab. *Journal of Crohn's and Colitis*, **2018**, 12, S450-S450	1.5	

33	P136 Association between histological indices and ulcerative colitis activity measures among patients in the HICKORY (etrolizumab) open-label induction cohort. *Journal of Crohn's and Colitis*, **2019**, 13, S157-S158	1.5
32	Endoscopie et MICI : pourquoi mettre à jour les recommandations de la SFED ?. *Acta Endoscopica*, **2013**, 43, 109-109	
31	Scores endoscopiques des maladies inflammatoires chroniques de l'intestin. *Acta Endoscopica*, **2014** , 44, 408-409	
30	Letter: anti-TNFs and psoriasis—friends or foes? Authors' reply. *Alimentary Pharmacology and Therapeutics*, **2012**, 36, 498-498	6.1
29	La cicatrisation muqueuse dans les MICI : pourquoi, quand et comment l'obtenir ?. *Acta Endoscopica*, **2012**, 42, 237-238	
28	Letter: fatigue, a growing concern in inflammatory bowel diseases. *Alimentary Pharmacology and Therapeutics*, **2013**, 38, 442	6.1
27	Evolution of IL-23 Blockade in Inflammatory Bowel Disease.. *Journal of Crohn's and Colitis*, **2022**, 16, ii1-ii2	2.5
26	DOP90 Efficacy of the treat-to-target approach in modifying disease course with ustekinumab in patients with moderate-to-severe Crohn's Disease: Results from the STARDUST trial. *Journal of Crohn's and Colitis*, **2022**, 16, i132-i134	1.5
25	P331 Composite outcomes in Crohn's disease: a systematic review and meta-analysis of observational studies. *Journal of Crohn's and Colitis*, **2022**, 16, i349-i350	1.5
24	P267 Milan Ultrasound Criteria are accurate in assessing endoscopic remission and treatment response in patients with ulcerative colitis. *Journal of Crohn's and Colitis*, **2022**, 16, i306-i307	1.5
23	Biosimilaires et maladies inflammatoires chroniques de l'intestin. *HEGEL - HEpato-GastroEntérologie Libérale*, **2016**, N° 1, 25-30	0.1
22	Advances in the treatment of ulcerative colitis. *Gastroenterology and Hepatology*, **2013**, 9, 827-9	0.7
21	Defining Severity in Inflammatory Bowel Disease. *Gastroenterology and Hepatology*, **2015**, 11, 474-6	0.7
20	Disease Modification in Crohn's Disease **2019**, 23-29	
19	DOP79 Dose escalation of upadacitinib in Crohn's disease patients with an inadequate response: Data from the randomised CELEST study. *Journal of Crohn's and Colitis*, **2020**, 14, S117-S118	1.5
18	Histoire naturelle de la maladie de Crohn **2011**, 105-114	
17	P682 Faecal calprotectin and C-reactive protein levels are associated with long-term clinical and endoscopic outcomes: Analysis of the OASIS open-label extension trial of etrasimod for ulcerative colitis. *Journal of Crohn's and Colitis*, **2020**, 14, S555-S556	1.5
16	New Paradigms to Help Decisions in Treatment Choice: Head to Head Trial of Biological Therapies in Inflammatory Bowel Diseases. *Current Drug Targets*, **2021**, 22, 370-378	3

15	Patients' real-world experience with inflammatory bowel disease: A cross-sectional survey in tertiary care centres from the GETAID group. *Digestive and Liver Disease*, **2021**, 53, 434-441	3.3
14	Reply. *Gastroenterology*, **2021**, 160, 1881	13.3
13	DOP88 Effect of risankizumab on patient-reported outcomes in patients with Crohn's Disease who had an inadequate response or intolerance to conventional and/or biologic treatments: Results from phase 3 MOTIVATE and ADVANCE trials. *Journal of Crohn's and Colitis*, **2021**, 15, S119-S121	1.5
12	Reply. *Gastroenterology*, **2021**, 160, 2223-2224	13.3
11	Reply to: Dr Macaluso's Letter. *Journal of Crohn's and Colitis*, **2016**, 10, 1452	1.5
10	P380 A prospective multi-centre observational cohort study assessing the effectiveness of Budesonide MMX® for mild-to-moderate ulcerative colitis. *Journal of Crohn's and Colitis*, **2019**, 13, S296-S297	1.5
9	Quality of Care in Ulcerative Colitis: A Modified Delphi Panel Approach. *Digestive Diseases*, **2018**, 36, 346-353	3.2
8	JAK inhibitors in crohn's disease: ready to go?. *Expert Opinion on Investigational Drugs*, **2022**, 1-17	5.9
7	Ranking treatments in the network meta-analysis should consider the certainty of evidence - Authors' reply.. *The Lancet Gastroenterology and Hepatology*, **2022**, 7, 288	18.8
6	Impact of abdominal or pelvic radiotherapy on disease activity in inflammatory bowel disease: a multicentre cohort study from the GETAID. *Alimentary Pharmacology and Therapeutics*, **2021**, 53, 400-409	6.1
5	Mucosal Healing in Crohn's Disease and Ulcerative Colitis.. *Gastroenterology and Hepatology*, **2020**, 16, 206-208	0.7
4	Corticosteroid-free efficacy and safety outcomes in patients receiving tofacitinib in the OCTAVE Sustain maintenance study.. *Therapeutic Advances in Gastroenterology*, **2022**, 15, 17562848221090834	4.7
3	Thérapies complémentaires et alternatives´: quelle place dans les maladies inflammatoires chroniques intestinales?. *HEGEL - HEpato-GastroEntérologie Libérale*, **2018**, N° 3, 190-198	0.1
2	Composite outcomes in observational studies of Crohn's disease: a systematic review and meta-analysis. *Therapeutic Advances in Gastroenterology*, **2022**, 15, 175628482210927	4.7
1	Re-Routing Infliximab Therapy: Subcutaneous Infliximab Opens a Path Towards Greater Convenience and Clinical Benefit. *Clinical Drug Investigation*,	3.2